SEC Company Response from Salarius Pharmaceuticals, Inc. (DCOY) (CIK 0001615219) (DCOY) — Feb 5, 2020
Salarius Pharmaceuticals, Inc. (DCOY) (CIK 0001615219)
Date: Feb. 5, 2020 · CIK: 0001615219 · Accession: 0001193125-20-025417
AI Filing Summary & Sentiment
File numbers found in text: 333-235879
Letter
Ladenburg Thalmann & Co. Inc.
999 Vanderbilt Beach Road, Suite 200
Naples, Florida 34108
February 5, 2020
VIA FACSIMILE AND EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Washington, DC 20549
Re: SALARIUS PHARMACEUTICALS, INC.
Registration Statement on Form S-1 (Registration No. 333-235879)
Concurrence in Acceleration Request
Ladies and Gentlemen:
Ladenburg Thalmann & Co. Inc. (“Ladenburg”), as representative of the underwriters for the referenced offering, hereby concurs in the request by Salarius Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:00 p.m. (Eastern Time), or as soon as practicable thereafter, on February 6, 2020, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Very truly yours,
LADENBURG THALMANN & CO. INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Ladenburg Thalmann & Co. Inc. 999 Vanderbilt Beach Road, Suite 200 Naples, Florida 34108 February 5, 2020 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Re: SALARIUS PHARMACEUTICALS, INC. Registration Statement on Form S-1 (Registration No. 333-235879) Concurrence in Acceleration Request Ladies and Gentlemen: Ladenburg Thalmann & Co. Inc. (“Ladenburg”), as representative of the underwriters for the referenced offering, hereby concurs in the request by Salarius Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:00 p.m. (Eastern Time), or as soon as practicable thereafter, on February 6, 2020, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act in connection with this offering. Very truly yours, LADENBURG THALMANN & CO. INC. By: /s/ Nicholas Stergis Name: Nicholas Stergis Title: Managing Director